Co-Authors
This is a "connection" page, showing publications co-authored by Olga Brawman-Mintzer and Jacobo Mintzer.
Connection Strength
0.952
-
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
Score: 0.203
-
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. J Neurotrauma. 2021 07 15; 38(14):1943-1952.
Score: 0.194
-
Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
Score: 0.184
-
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry. 1996; 57 Suppl 7:55-63; discussion 73-5.
Score: 0.135
-
Attentional functioning in patients with posttraumatic stress disorder: a preliminary study. CNS Spectr. 2013 Apr; 18(2):90-4.
Score: 0.110
-
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
Score: 0.046
-
Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry. 1998 Nov 01; 44(9):918-21.
Score: 0.041
-
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
Score: 0.039